Jubilant Ingrevia Ltd
JUBLINGREAJubilant Ingrevia Ltd
JUBLINGREA![](https://assets.tickertape.in/sector-icons/materials.png)
![](https://assets.tickertape.in/sector-icons/smallcap.png)
![](https://assets.tickertape.in/sector-icons/moderate_risk.png)
Price Chart
How to use scorecard? Learn more
Key Metrics
No LabelNo Label | PB RatioPB Ratio | Dividend YieldDiv. Yield |
---|---|---|
58.39 | 3.71 | 0.78% |
Sector PESector PE | Sector PBSector PB | Sector Div YldSctr Div Yld |
---|---|---|
31.64 | 3.63 | 1.25% |
Forecast & Ratings
Detailed Forecast from 3 analysts
Price
Price Upside
Earnings
Earnings Growth
Revenue
Rev. Growth
Company Profile
Jubilant Ingrevia is engaged in the business of integrated life science products.
Peers
Compare with peersGujarat Fluorochemicals Ltd
Aarti Industries Ltd
Vinati Organics Ltd
Fine Organic Industries Ltd
Supreme Petrochem Ltd
Get more out of Tickertape, Go Pro!
Customise key metrics, see detailed forecasts, download stock data and more
Forecasts
Price
Revenue
Earnings
Price Forecast
All values in ₹
All values in ₹
Revenue Forecast
All values in ₹ Thousand cr.
All values in ₹ Thousand cr.
Earnings Per Share Forecast
All values in ₹
All values in ₹
Income
Balance Sheet
Cash Flow
Income Statement
Financial Year | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | TTM | ||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
Total Revenue | 0.00 | 686.73 | 4,980.85 | 4,806.06 | 4,171.12 | 4,121.72 | ||||||
Raw Materials | 0.00 | 379.46 | 2,984.96 | 2,709.31 | 2,089.45 | 3,671.17 | ||||||
Power & Fuel Cost | 0.00 | 51.71 | 468.23 | 722.83 | 539.98 | |||||||
Employee Cost | 0.00 | 49.02 | 327.28 | 343.48 | 383.95 | |||||||
Selling & Administrative Expenses | 0.17 | 34.41 | 208.60 | 271.70 | 358.69 | |||||||
Operating & Other expenses | 0.00 | 65.35 | 128.52 | 178.26 | 342.62 | |||||||
EBITDA | -0.17 | 106.78 | 863.26 | 580.48 | 456.43 | 450.55 | ||||||
Depreciation/Amortization | 0.00 | 22.06 | 123.39 | 122.18 | 136.17 | 142.75 | ||||||
PBIT | -0.17 | 84.72 | 739.87 | 458.30 | 320.26 | 307.80 | ||||||
Interest & Other Items | 0.00 | 7.33 | 30.94 | 21.58 | 52.66 | 55.47 | ||||||
PBT | -0.17 | 77.39 | 708.93 | 436.72 | 267.60 | 252.33 | ||||||
Taxes & Other Items | 0.00 | 23.03 | 232.23 | 129.22 | 84.72 | 78.29 | ||||||
Net Income | -0.17 | 54.36 | 476.70 | 307.50 | 182.88 | 174.04 | ||||||
EPS | -3.40 | 6.80 | 29.96 | 19.32 | 11.48 | 10.93 | ||||||
DPS | 0.00 | 0.35 | 5.00 | 5.00 | 5.00 | 5.00 | ||||||
Payout ratio | 0.00 | 0.05 | 0.17 | 0.26 | 0.44 | 0.46 |
Company Updates
Annual report
PDFPeers & Comparison
MaterialsSpecialty Chemicals
Valuation
Technical
Forecast
Stock | PE RatioPE Ratio | PB RatioPB Ratio | Div. YieldDividend Yield |
---|---|---|---|
Jubilant Ingrevia Ltd | 55.57 | 3.71 | 0.78% |
Gujarat Fluorochemicals Ltd | 80.98 | 6.38 | 0.09% |
Aarti Industries Ltd | 54.73 | 4.31 | 0.16% |
Vinati Organics Ltd | 63.19 | 8.29 | 0.36% |
Price Comparison
Compare JUBLINGREA with any stock or ETFShareholdings
Promoter Holdings Trend
Institutional Holdings Trend
Total Retail Holding
In last 3 months, retail holding in the company has almost stayed constant
Foreign Institutional Holding
In last 3 months, foreign institutional holding of the company has almost stayed constant
Shareholding Pattern
Sep 2023
Dec 2023
Mar 2024
Jun 2024
Shareholding History
Mutual Funds Holding Trend
Mutual Fund Holding
In last 3 months, mutual fund holding of the company has almost stayed constant
Top 5 Mutual Funds holding Jubilant Ingrevia Ltd
Funds (Top 5) | The rupee value of the stock held by the fund divided by the stock’s market cap Market-cap held | Percentage of the fund’s portfolio invested in the stock Weight | Change in the portfolio weight of the stock over the last 3 months 3M holding change | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months Portfolio rank(3M change) |
---|---|---|---|---|
DSP Small Cap Fund - Growth - Direct Plan Growth | The rupee value of the stock held by the fund divided by the stock’s market cap 4.7274% | Percentage of the fund’s portfolio invested in the stock 2.99% | Change in the portfolio weight of the stock over the last 3 months 0.06% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 42/83 (+1) |
DSP Midcap Fund - Growth - Direct Plan Growth | The rupee value of the stock held by the fund divided by the stock’s market cap 2.5453% | Percentage of the fund’s portfolio invested in the stock 1.35% | Change in the portfolio weight of the stock over the last 3 months -0.10% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 16/69 (+26) |
Edelweiss Small Cap Fund - Growth - Direct Plan Growth | The rupee value of the stock held by the fund divided by the stock’s market cap 0.7775% | Percentage of the fund’s portfolio invested in the stock 1.98% | Change in the portfolio weight of the stock over the last 3 months -0.17% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 8/76 (-1) |
Compare 3-month MF holding change on Screener
smallcases
Looks like this stock is not in any smallcase yet.
Events
Dividend Trend
No dividend trend available
Dividends
Corp. Actions
Announcements
Legal Orders
Upcoming Dividends
No upcoming dividends are available
Past Dividends
Cash Dividend
Ex DateEx DateAug 2, 2024
Dividend/Share
₹2.50
Ex DateEx Date
Aug 2, 2024
Cash Dividend
Ex DateEx DateFeb 9, 2024
Dividend/Share
₹2.50
Ex DateEx Date
Feb 9, 2024
Cash Dividend
Ex DateEx DateAug 10, 2023
Dividend/Share
₹2.50
Ex DateEx Date
Aug 10, 2023
Cash Dividend
Ex DateEx DateFeb 10, 2023
Dividend/Share
₹2.50
Ex DateEx Date
Feb 10, 2023
Cash Dividend
Ex DateEx DateAug 23, 2022
Dividend/Share
₹2.50
Ex DateEx Date
Aug 23, 2022
Jubilant Ingrevia announced that the 5th Annual General Meeting (AGM) of the company will be held on 30 August 2024.Powered by Capital Market - Live
Buy Jubilant Ingrevia, target price Rs 735: Anand Rathi
![](https://pocket-image-cache.com/direct?url=http://img.etimg.com/thumb/msid-112124019,width-1200,height-630,imgsize-523157,overlay-etmarkets/photo.jpg)
Jubilant Ingrevia has redeemed commercial paper of Rs 100 crore on maturity date of 25 July 2024. Powered by Capital Market - Live
Jubilant Ingrevia slips after Q1 PAT slides 15% YoY to Rs 48 cr in FY25
![](https://pocket-image-cache.com/direct?url=http://www.business-standard.com/assets/web-assets/images/Business_Standard_685x385.jpg)
Jubilant Ingrevia Q1 PAT slides 15% YoY to Rs 48 cr in FY25
![](https://pocket-image-cache.com/direct?url=http://www.business-standard.com/assets/web-assets/images/Business_Standard_685x385.jpg)
During the quarter, total revenue from operations stood at Rs 1,024.34 crore in Q1 FY25, down 4.71% from Rs 1,075.02 crore in Q1 FY24. Profit before tax stood at Rs 66.03 crore in the first quarter of FY25, reporting a growth of 23.14% from Rs 81.31 crore in Q1 FY24. EBITDA declined 5% to Rs 119 crore in Q1 FY25 as against Rs 125 crore in Q1 FY24. EBITDA margin remains constant at 12% in Q1 FY25 as compared with recorded in same quarter last year. The company said that the volumes of Pyridine and Diketene derivatives witnessed a rising trend, while demand for Niacinamide & Pyrithiones remained steady. In acetyls, it remained focused towards maintaining market share, despite challenges being faced due to lower demand, container unavailability and a decline in acetic acid prices. Strong traction continued in CDMO business, wherein the company started delivery of new orders during the quarter. It is also in advanced-stage discussions for multiple projects in Pharma, Agro and semi-conductor end-use. Revenue from specialty chemicals grew by 8.25% YoY to Rs 475.33 crore in Q1 FY25, driven by increased on a YoY basis on account of higher volumes coming from pyridine building blocks, diketene and fine chemicals. Revenue from nutrition & health solutions fell 7.87% YoY to Rs 186.34 crore in Q1 FY25, on account of sequential higher volumes from human end-use and cosmetic-grade products. Revenue from chemical intermediates declined 19.73% on YoY to Rs 410.28 crore in first quarter of FY25. EBITDA declined 41% to Rs 36 crore. The company said that revenue for the quarter was lower, although volumes remained steady. EBITDA during the quarter was impacted on account of higher ocean freight costs, mainly led by the container Crisis and overall realisations remaining subdued. On outlook front, the company reaffirms its expectation of witnessing improvements in all three business segments in FY25 over FY24. Like last quarter, its key focus remains customer-centricity, ramping up the newly commissioned plants, remaining lean and bringing back the margins to normal levels. The company is focused towards keeping the costs in control through its Project Lean and is on track to source renewable energy for long-term energy requirements, which also underscores firm commitment towards sustainability & environment. Its continue to see increasing utilisation of newly created plants, and remain on track with its capex plans towards investing in high-potential product categories to deliver on bold vision of Pinnacle 345, 3 times Revenue, 4 times EBIDTA, in 5 years. Shyam S Bhartia, chairman, Jubilant Ingrevia, said, 'The Pharmaceutical end-use segment, continues to witness rising demand trends with healthy volume placements. We are also glad to share that we have gained significant traction in the regulated markets of North America, Europe & Japan. We are witnessing continuous pressure on Acetyl segment owing to lower demand coming from the Paracetamol end-use segment. The agrochemical sector has started to show marginal improvement. While the excess inventory situation is gradually easing out and volumes have started to move, the prices still remain under pressure due to the excess supply of agrochemicals globally. In the nutrition segment, the demand remained steady in line with the previous two quarters, and prices also moved up marginally towards the end of the quarter, except for Choline where Chinese imports remained aggressive.' The company's manufacturing facility at Bharuch, Gujarat has successfully completed its USFDA inspection with zero 483 observations. This good manufacturing practice (GMP)-compliant facility is meant for manufacturing nutraceuticals and dietary active ingredients. Jubilant Ingrevia is a global integrated life science products and innovative solutions provider serving, pharmaceutical, nutrition, agrochemical, consumer and industrial customers with its customised products and solutions that are innovative, cost effective and conforming to premium quality standards. The company is engaged in manufacturing and supply of speciality chemicals, nutrition & health solutions and chemical intermediates through five manufacturing facilities in India. Shares of Jubilant Ingrevia rose 0.37% to end at Rs 586.60 on Tuesday, 16 July 2024. The domestic market is closed today on account of Moharram.Powered by Capital Market - Live
Jubilant Ingrevia consolidated net profit declines 15.37% in the June 2024 quarter
![](https://pocket-image-cache.com/direct?url=http://www.business-standard.com/assets/web-assets/images/Business_Standard_685x385.jpg)
Stock Alert: Jio Financial Services, Spicejet, Hatsun Agro Product, Hindustan Unilever (HUL)
![](https://pocket-image-cache.com/direct?url=http://www.business-standard.com/assets/web-assets/images/Business_Standard_685x385.jpg)
Volumes soar at Jubilant Ingrevia Ltd counter
![](https://pocket-image-cache.com/direct?url=http://www.business-standard.com/assets/web-assets/images/Business_Standard_685x385.jpg)
Bombay Burmah Trading Corporation Ltd leads gainers in ‘A’ group
![](https://pocket-image-cache.com/direct?url=http://www.business-standard.com/assets/web-assets/images/Business_Standard_685x385.jpg)
Total Promoter Holding
In last 6 months, promoter holding in the company has almost stayed constant
Low Pledged Promoter Holding
Pledged promoter holdings is insignificant